Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 656-658

  Gubareva, Larisa V ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR;

FERRET; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FERRETS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RISK ASSESSMENT;

EID: 76449104604     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650465     Document Type: Note

References (19)

1. Baz M, Abed Y, Simon P, Hamelin MEÈ, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010; 2001:740-745 (in this issue).
2. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-1630.
3. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antivir Res 2002; 54:99-111.
4. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-3390.
5. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49:4075-4084.
6. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
7. Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009; 301: 1042-1046.
8. Hauge SH, Dudman S, Borgen K, et al. Oseltamivir- resistant influenza viruses A (H1N1), Norway, 2007-2008. Emerg Infect Dis 2009; 15: 155-162.
9. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H275Y neuraminidase mutation. J Infect 2009; 59:207-212.
10. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections [review]. Rev Med Virol 2002; 12:159-166.
11. Domingo E, Holland JJ. RNA virus mutations and fitness for survival [review]. Annu Rev Microbiol 1997; 51:151-178.
12. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/ H1N1 viruses selected in vitro with peramivir and zanamivir. Antivir Res 2007; 74:159-162.
13. Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-8425.
14. Hatakeyama S, Sakai-Tagawa Y, Kiso M, et al. Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 2005; 43:4139-4146.
15. Rameix-Welti MA, Enouf V, Cuvelier F, et al. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008; 4:e1000103.
16. Yen HL, Ilyushina NA, Salomon R, et al. Neuraminidase inhibitor-resistant recombinant A/ Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 2007; 81: 12418-12426.
17. Ives JA, Carr JA, Mendel DB, et al. The H275Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research 2002; 55:307-317.
18. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
19. Hurt AC, Holien JK, Parker M, et al. Zanamivir- resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83: 10366-10373.